Overview

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Status:
Active, not recruiting

Trial end date:
2022-03-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.

Phase:

Phase 2

Details

Lead Sponsor:

Shire

Collaborator:

Takeda Development Center Americas, Inc.